• Go to navigation
  • Go to content
AstraZeneca

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca United States

Main navigation

  • Home
  • Our medicines
  • Responsibility
  • Community support
  • Help affording your medicines
  • Research & development
  • Health care professionals
  • HealthCare Foundation
  • Careers
  • About AstraZeneca US
    • Our company
    • AZ on the issues
    • Investors
    • Newsroom
      • All news
      • Corporate news
      • Financial news
      • Product news
      • Research news
      • Media resources
    • US Websites
    • Social media sites
    • Contact us

You are here

  • Home
  • About AstraZeneca US
  • Newsroom
  • Research news

The following shows headlines of research-related news articles published within 12-months, starting from most recent.


Date

    • Jan 19, 2012
    • Bristol-Myers Squibb and AstraZeneca receive complete response letter from U.S. Food and Drug Administration for dapagliflozin  
    • Aug 1, 2011
    • AstraZeneca announces U.S. enrollment opportunities for KODIAC study to investigate an experimental drug for constipation from opioids  
    • May 18, 2011
    • Phase II study results evaluating effect of olaparib on progression free survival in serous ovarian cancer announced today  

Page tools

  • Print
  • Bookmark this page
  • Subscribe to RSS news feed

Stay connected with us

Stay connected with us on our social media sites

  • Stay connected with us on our social media sites

Please note

These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.

Click here for information on AstraZeneca products, including their current US Prescribing Information.

Legal notices

  • Legal Information
  • Privacy Statement
  • © AstraZeneca 2012